secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entrada Therapeutics, Inc. (TRDA)
CIK:        0001689375
Form:       8-K
Filed at:   2022-05-12T23:59:59+00:00
Accession:  0001104659-22-059069
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 9.01, 2.02
LLM model:  deepseek-v4-flash:cloud@v2

Entrada Q1 net loss $21.7M; announces second candidate ENTR-701 for DM1; IND on track for Q4 2022
--------------------------------------------------------------------------------

- Q1 2022 net loss of $21.7M vs $8.4M YoY; R&D expenses rose to $15.7M from $6.2M.
- Cash, equivalents & marketable securities $263.9M at March 31 (down from $291.1M); runway into H2 2024.
- Announced ENTR-701 as second clinical candidate for myotonic dystrophy type 1 (DM1).
- On track to submit IND for ENTR-601-44 (Duchenne MD, exon 44 skipping) in Q4 2022.
- Preclinical data showed durable exon 44 skipping in NHP biceps for at least 12 weeks after single dose of ENTR-601-44.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689375/000110465922059069/0001104659-22-059069-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689375/000110465922059069/tm2215094d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-059069

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer